Core Insights - ZimVie Inc. has launched its RealGUIDE Software Suite and Implant Concierge service in Japan, enhancing access to a digital dental implant ecosystem [1][2] - The Japanese dental implant market is significant, representing ZimVie's largest market in the APAC region [1] Product Offerings - RealGUIDE software provides comprehensive tools for precise implant planning, surgical guides, and restorative design, aimed at improving patient care and operational efficiencies [2] - The software is the first complete cloud-based solution of its kind, consisting of multiple modules for thorough diagnosis and advanced design [2] - Implant Concierge is a virtual outsourcing service that simplifies implant treatment planning and guided surgery, designed for high-volume practices [3] Market Opportunity - The rising adoption of dental implants presents a substantial growth opportunity, necessitating more efficient and integrated treatment workflows [4] - Digital dentistry is becoming the new standard in implantology, with ZimVie experiencing strong traction in other markets [4]

Summary of Zimvi's Conference Call Company Overview - **Company**: Zimvi - **Industry**: Dental Implants and Digital Dentistry - **Key Products**: TSX implant, T3 Pro implant, Real Guide software, Implant Concierge, Puros Allografts, Immediate Molar Implant Core Points and Arguments 1. **Market Opportunity**: In the U.S., there are approximately 8 million candidates for tooth replacement, but only 25% receive dental implants, indicating significant growth potential in the market [4][5][6] 2. **Adoption and Education**: Zimvi focuses on increasing adoption of dental implants through training and education for both staff and referring dentists, emphasizing the importance of clinical outcomes and customer experience [5][6][7] 3. **Product Innovation**: 43% of Zimvi's sales come from products launched in the last three years, showcasing a strong innovation pipeline [9][58] 4. **Digital Dentistry**: The company is investing in digital solutions, including AI and cloud-based software, to enhance workflow and patient experience, with Real Guide software seeing a 39% growth in 2024 [10][24][29] 5. **Financial Performance**: Despite headwinds, Zimvi reported a 41% improvement in EBITDA and a 238% increase in EPS, indicating strong operational efficiency [35][36] 6. **Growth Projections**: For the full year, Zimvi anticipates flat to 3% growth in top-line revenue, with adjusted EBITDA growth of 17% and adjusted EPS growth of 31% to 55% [37] Additional Important Insights 1. **Market Dynamics**: The dental implant market is underpenetrated, and Zimvi aims to capture more market share through new product introductions and improved customer relationships [8][12] 2. **Full Arch Market**: Zimvi has increased its share in the full arch market from 5% to approximately 8.5-9%, with plans to further enhance this segment [22][44] 3. **Cost Management**: The company has improved gross margins by 360 basis points through cost reductions and operational efficiencies, with aspirations to reach over 70% gross margin in the long term [50][52] 4. **Pent-Up Demand**: There is potential for pent-up demand in the dental market as consumer sentiment improves and interest rates decrease, which could lead to accelerated growth [54][56] 5. **Customer Retention**: The renewal rate for Real Guide software exceeds 90%, indicating strong customer loyalty and satisfaction [61] Conclusion Zimvi is positioned for growth in the dental implant market through strategic product innovation, digital transformation, and operational efficiencies. The company is optimistic about capturing additional market share and improving financial performance in the coming years.

PALM BEACH GARDENS, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming Stifel 2025 Jaws & Paws Conference. Management will be presenting on Wednesday, May 28, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie’s investor website at investor.zimvie.com. About ZimVieZimVie is a global lif ...

A Global Dental Leader May 2025 1 Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "ta ...

ZimVie (ZIMV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Webb Campbell - Vice PresidentVafa Jamali - Chairman, President & CEORich Heppenstall - EVP, CFO & Treasurer Conference Call Participants Dylan Finley - Equity Research AnalystAnderson Schock - Medtech Equity Research AnalystMatt Miksic - Equity Research Analyst Operator Good afternoon, and welcome to ZIMVY's First Quarter twenty twenty five Earnings Conference Call. Currently, all participants are in a listen only mode. We wi ...

ZimVie (ZIMV) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to ZIMVY's First Quarter twenty twenty five Earnings Conference Call. Currently, all participants are in a listen only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Webb Campbell from Gilmartin Group for today's introductory disclosures. Speaker1 Thank you all ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Exact Name of Registrant as Specified in its Charter) | Delaware | 87-2007795 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 4555 Riverside Drive | | | Palm Beach Gardens, FL | 33410 | | (Address of principal executive offices) | (Zip Code) | | | Registrant's telephone number, including area code: (800) 342-5454 | Securities registered pursuant t ...

[Financial Performance and Outlook](index=1&type=section&id=Financial%20Performance%20and%20Outlook) This section details ZimVie's first quarter 2025 financial results and provides full-year 2025 financial guidance [First Quarter 2025 Financial Results](index=1&type=section&id=First%20Quarter%202025%20Financial%20Results) ZimVie reported a 5.2% decrease in net sales to $112.0 million for Q1 2025, but showed significant profitability improvements, with net loss narrowing to $(2.6) million and adjusted EBITDA increasing to $17.6 million - The company entered 2025 with a strong focus on execution and operational diligence, aiming to improve operational efficiency and profitability while working towards a return to top-line growth[3](index=3&type=chunk) Q1 2025 Financial Performance vs. Q1 2024 (Continuing Operations) | Financial Metric | Q1 2025 | Q1 2024 | Change | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Net Sales | $112.0M | $118.2M | -$6.2M | -5.2% | | Net Loss | $(2.6)M | $(11.5)M | +$8.9M | N/A | | Net Loss Margin | (2.3)% | (9.7)% | +740 bps | N/A | | Adjusted Net Income | $7.4M | $2.2M | +$5.2M | +236% | | Adjusted EBITDA | $17.6M | $12.5M | +$5.1M | +40.8% | | Adjusted EBITDA Margin | 15.7% | 10.5% | +520 bps | N/A | | Diluted EPS | $(0.09) | $(0.42) | +$0.33 | N/A | | Adjusted Diluted EPS | $0.27 | $0.08 | +$0.19 | +237.5% | [Full Year 2025 Financial Guidance](index=1&type=section&id=Full%20Year%202025%20Financial%20Guidance) The company provides its financial outlook for the full year ending December 31, 2025, projecting net sales between $445 million and $460 million and adjusted EPS in the range of $0.80 to $0.95 Full Year 2025 Financial Guidance (Continuing Operations) | Metric | Guidance Range | | :--- | :--- | | Net Sales | $445M to $460M | | Adjusted EBITDA | $65M to $70M | | Adjusted EPS | $0.80 to $0.95 | - The forward-looking guidance for Adjusted EBITDA and Adjusted EPS are non-GAAP financial measures, with reconciliation to GAAP measures not available without unreasonable efforts[8](index=8&type=chunk) [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) This section presents ZimVie's consolidated financial statements, including the statement of operations, balance sheets, and cash flows for the reported periods [Consolidated Statement of Operations](index=4&type=section&id=Consolidated%20Statement%20of%20Operations) For the first quarter of 2025, ZimVie reported an operating profit of $0.78 million, a significant turnaround from an operating loss of $(2.73) million in the prior-year period, with net loss from continuing operations improving to $(2.63) million Statement of Operations Highlights (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Sales | $111,997 | $118,195 | | Operating Profit (Loss) | $780 | $(2,732) | | Net Loss from Continuing Operations | $(2,625) | $(11,483) | | Net Loss of ZimVie Inc. | $(1,471) | $(7,761) | | Diluted EPS from Continuing Operations | $(0.09) | $(0.42) | [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, ZimVie's total assets were $745.8 million, a slight decrease from $753.7 million at year-end 2024, while total liabilities decreased and total stockholders' equity increased Balance Sheet Highlights (in thousands) | Line Item | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $66,750 | $74,974 | | Total Current Assets | $250,658 | $257,285 | | Total Assets | $745,782 | $753,674 | | Total Current Liabilities | $117,144 | $133,944 | | Total Liabilities | $350,659 | $371,967 | | Total Stockholders' Equity | $395,123 | $381,707 | [Consolidated Statements of Cash Flows](index=6&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) The company used $13.9 million in cash from operating activities in Q1 2025, an increase from the $11.5 million used in Q1 2024, ending the period with $66.8 million in cash and cash equivalents Cash Flow Highlights (in thousands) | Line Item | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(13,911) | $(11,511) | | Net cash used in investing activities | $(1,947) | $(4,138) | | Net cash used in financing activities | $(1,135) | $(1,437) | | Decrease in cash and cash equivalents | $(9,822) | $(19,184) | | Cash and cash equivalents, end of period | $66,750 | $68,584 | [Reconciliation of Non-GAAP Financial Measures](index=7&type=section&id=Reconciliation%20of%20Non-GAAP%20Financial%20Measures) This section provides reconciliations of various non-GAAP financial measures, including constant currency net sales, adjusted net income, adjusted EBITDA, and adjusted operating expenses [Reconciliation of Constant Currency Net Sales](index=7&type=section&id=Reconciliation%20of%20Constant%20Currency%20Net%20Sales) This section details the impact of foreign currency exchange rates on net sales, showing a 5.2% reported decrease but a smaller 4.1% decrease on a constant currency basis for Q1 2025 Q1 2025 Net Sales Change: Reported vs. Constant Currency | Region | Reported Change (%) | Foreign Exchange Impact | Constant Currency Change (%) | | :--- | :--- | :--- | :--- | | United States | (2.8%) | 0.0% | (2.8%) | | International | (8.5%) | (2.6%) | (5.9%) | | **Total Net Sales** | **(5.2%)** | **(1.1%)** | **(4.1%)** | [Reconciliation of Adjusted Net Income and Diluted EPS](index=8&type=section&id=Reconciliation%20of%20Adjusted%20Net%20Income%20and%20Diluted%20EPS) ZimVie's reported GAAP net loss of $(2.6) million and EPS of $(0.09) were adjusted for various items, resulting in a non-GAAP adjusted net income of $7.4 million and an adjusted diluted EPS of $0.27 for Q1 2025 Reconciliation of Net Income (Loss) to Adjusted Net Income (in thousands) | Description | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Reported Net (Loss) Income** | **$(2,625)** | **$(11,483)** | | Intangible asset amortization | $6,032 | $6,022 | | Restructuring and other cost reduction initiatives | $1,432 | $2,579 | | Acquisition, integration, divestiture and related | $1,449 | $1,037 | | Other adjustments | $600 | $1,088 | | Tax effect of adjustments & other | $484 | $3,316 | | **Adjusted Net Income** | **$7,371** | **$2,158** | - Major adjustments for Q1 2025 include costs related to restructuring, professional services fees for the spine segment sale, and intangible asset amortization[29](index=29&type=chunk)[30](index=30&type=chunk) [Reconciliation of Adjusted EBITDA](index=9&type=section&id=Reconciliation%20of%20Adjusted%20EBITDA) The company reconciles its Q1 2025 net loss of $(2.6) million to an adjusted EBITDA of $17.6 million, representing a significant increase from $12.5 million in Q1 2024 and an improved margin of 15.7% Reconciliation of Net Loss to Adjusted EBITDA (in thousands) | Description | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Net Loss** | **$(2,625)** | **$(11,483)** | | Interest expense, net | $2,017 | $4,366 | | Income tax provision | $3,074 | $4,074 | | Depreciation and amortization | $8,655 | $8,430 | | **EBITDA** | **$11,121** | **$5,387** | | Share-based compensation | $3,497 | $2,762 | | Restructuring and other cost reduction initiatives | $1,432 | $2,579 | | Acquisition, integration, divestiture and related | $1,449 | $1,037 | | Other adjustments | $62 | $687 | | **Adjusted EBITDA** | **$17,561** | **$12,452** | [Reconciliation of Cost of Products Sold, R&D and SG&A](index=10&type=section&id=Reconciliation%20of%20Cost%20of%20Products%20Sold%2C%20R%26D%20and%20SG%26A) This section provides adjusted figures for key operating expense lines, with adjusted cost of products sold at 33.6% of net sales, adjusted R&D at 4.8%, and adjusted SG&A at 52.4% for Q1 2025 Adjusted Operating Expenses as a Percentage of Net Sales | Expense Line | Q1 2025 (Adjusted) | Q1 2024 (Adjusted) | | :--- | :--- | :--- | | Cost of products sold, excluding intangible asset amortization | 33.6% | 37.2% | | Research and development | 4.8% | 5.3% | | Selling, general and administrative | 52.4% | 51.0% | - Adjustments in Q1 2025 were made for regulatory costs related to the separation from ZBH and the net impact of converting performance-based RSUs to time-based RSUs[38](index=38&type=chunk)[39](index=39&type=chunk) [Supplementary Information](index=2&type=section&id=Supplementary%20Information) This section provides an overview of ZimVie, details regarding the conference call, and important notes on non-GAAP financial measures and forward-looking statements [About ZimVie and Conference Call](index=2&type=section&id=About%20ZimVie%20and%20Conference%20Call) This section provides a corporate overview of ZimVie as a global leader in the dental market, headquartered in Palm Beach Gardens, Florida, and announces the conference call scheduled for May 8, 2025 - ZimVie is a global life sciences leader in the dental market, offering a comprehensive portfolio for tooth replacement and restoration procedures[10](index=10&type=chunk) - A conference call to discuss Q1 2025 results was scheduled for May 8, 2025, at 4:30 p.m. ET[9](index=9&type=chunk) [Note on Non-GAAP Financial Measures and Forward-Looking Statements](index=2&type=section&id=Note%20on%20Non-GAAP%20Financial%20Measures%20and%20Forward-Looking%20Statements) The company explains its use of non-GAAP financial measures, stating they provide meaningful incremental information for investors, and includes a standard cautionary note regarding various risks and uncertainties affecting future results - The press release uses non-GAAP measures (e.g., constant currency, adjusted net income, adjusted EBITDA) which management believes help evaluate business performance and trends by allowing for period-to-period comparisons without the distortion of certain items[11](index=11&type=chunk)[17](index=17&type=chunk) - The report contains forward-looking statements subject to significant risks and uncertainties, including dependence on new products, pricing pressures, regulatory changes, and general economic conditions, cautioning readers not to place undue reliance on them[20](index=20&type=chunk)

Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financ ...

PALM BEACH GARDENS, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before th ...